Bifogade filer
ENG Q2 2022 BICO Final
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Strong sales despite external challenges
BICO Group AB 559050-5052 (NASDAQ STOCKHOLM: BICO)
BICO is the future of life-saving treatments. We are reducing the organ shortage and speeding up drug development by providing accessible life science solutions that combine biology and technology.
APRIL – JUNE 2022
(COMPARED WITH APRIL – JUNE 2021)
- Net sales amounted to MSEK 537.6 (293.1), which corresponds to an increase of 83% (628) compared to the corresponding period previous year.
- Organic growth for the period amounted to 7% (95).
- EBITDA amounted to MSEK -62.9 (10.6), corresponding to a margin of -11.7% (3.6).
- Adjusted EBITDA amounted to MSEK 11.1 (21.5), corresponding to a margin of 2.1% (7.3)
- Net profit/loss for the period amounted to MSEK 43.1 (-50.5), corresponding to earnings per share before and after dilution of SEK 0.68 (-0.89).
- The gross margin amounted to 73.0% (69.1). The gross margin structure in the acquired companies 2021 varies depending on the product mix.
JANUARY – JUNE 2022
(COMPARED WITH JANUARY – JUNE 2021)
- Net sales amounted to MSEK 1,014.8 (422.6), which corresponds to an increase of 140% (440) compared to the corresponding period previous year.
- Organic growth for the period amounted to 21% (79).
- EBITDA amounted to MSEK -82.3 (-24.3), corresponding to margin of -8.1% (-5.8).
- Adjusted EBITDA amounted to MSEK 17.1 (8.7), corresponding to a margin of 1.7% (2.1).
- Net profit/loss for the period amounted to MSEK -0.4 (-98.3), corresponding to earnings per share before and after dilution of SEK 0.00 (-1.78).
- The gross margin amounted to 73.4% (72.5). The gross margin structure in the acquired companies 2021 varies depending on the product mix.
“The company pulse is strong. We have a tremendous portfolio of products and services that contribute to the future of life-saving treatments.” ERIK GATENHOLM / PRESIDENT & CEO
Q2 KEY TAKEAWAYS
- Highest turnover ever
- Cash flow improvement measures
- Strengthened finance processes
- Continued success in innovation
- Focus on operational efficiency and acquisition synergies
- Cost reduction program decided after the end of the period
INVITATION TO PRESENTATION:
Join us for combined presentation audiocasts and telephone conferences with the opportunity to ask questions at 09:00 CEST and 16:00 CEST on August 24, 2022, with President & CEO Erik Gatenholm and Interim CFO Mikael Engblom.
The presentation audiocasts will be accessible via the following links:
Morning audiocast, at 09:00 CEST:
https://tv.streamfabriken.com/bico-q2-2022-am
To participate via telephone, please call any of the following numbers:
SE: +46 8 505 163 86
UK: +44 203 198 4884
US: +1 412 317 6300
PIN for all numbers: 3144420#
Afternoon audiocast, at 16:00 CEST:
https://tv.streamfabriken.com/bico-q2-2022-pm
To participate via telephone, please call any of the following numbers:
SE: +46 8 505 163 86
UK: +44 203 198 4884
US: +1 412 317 6300
PIN for all numbers: 3505431#
The presentation will also be available on the company’s website:
https://bico.com/investors/financials/financial-reports-and-presentations/